Axon holder Patrick W. Smith plans $5.06M sale

AXON ENTERPRISE, INC.

Rhea-AI Filing Summary

AXON ENTERPRISE, INC. (AXON) is the issuer for a Rule 144 notice filed for the account of Patrick W. Smith, covering a proposed sale of 10,000 shares of Axon common stock through UBS Financial Services Inc. The shares relate to an option exercise on November 15, 2021, to be sold for cash. As of September 8, 2026, Axon had 81,237,415 common shares outstanding; this is a baseline figure, not the amount being offered. The notice also lists prior sales by Smith over the past three months, each for 10,000 shares of common stock.

Key Figures

Shares to be sold: 10,000 shares Aggregate amount for covered shares: $5,060,300.00 Shares outstanding: 81,237,415 shares +4 more

7 metrics

Shares to be sold 10,000 shares Proposed sale of Axon common stock under Rule 144

Aggregate amount for covered shares $5,060,300.00 Securities information for 10,000 shares of Axon common stock

Shares outstanding 81,237,415 shares Axon common stock outstanding as of September 8, 2026

Prior sale June 29, 2026 10,000 shares; $5,000,018.00 Common stock sold by Patrick W. Smith

Prior sale July 7, 2026 10,000 shares; $6,437,894.85 Common stock sold by Patrick W. Smith

Prior sale August 7, 2026 10,000 shares; $5,488,963.00 Common stock sold by Patrick W. Smith

Option exercise date November 15, 2021 Source of shares to be sold

Key Terms

Rule 144, option exercise, attorney-in-fact, Nasdaq

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

option exercise financial

"Common | 11/15/2021 | Option Exercise | Issuer"

attorney-in-fact regulatory

"UBS Financial Services Inc, as attorney-in-fact for Patrick W. Smith"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

Nasdaq market

"09/08/2026 | Nasdaq"

The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for AXON disclose?

It discloses that Patrick W. Smith intends to sell 10,000 shares of Axon Enterprise, Inc. common stock under Rule 144 through UBS Financial Services Inc., with the shares tied to an option exercise on November 15, 2021.

How many Axon (AXON) shares are covered by this Rule 144 notice?

The notice covers a proposed sale of 10,000 shares of Axon Enterprise, Inc. common stock, to be sold for cash through UBS Financial Services Inc. as broker.

What prior sales by Patrick W. Smith in AXON shares are reported?

The notice reports three prior sales: 10,000 shares on June 29, 2026 for $5,000,018.00, 10,000 shares on July 7, 2026 for $6,437,894.85, and 10,000 shares on August 7, 2026 for $5,488,963.00.

How many Axon (AXON) shares were outstanding as of the date in the notice?

As of September 8, 2026, Axon Enterprise, Inc. had 81,237,415 shares of common stock outstanding; this figure provides context and is not the amount being sold under the notice.

What is the aggregate value associated with the AXON shares in this Rule 144 filing?

The securities information section lists an aggregate amount of $5,060,300.00 related to the 10,000 shares of Axon common stock covered by the Rule 144 notice.

Who is acting on behalf of the seller in the AXON Form 144?

The signature block shows UBS Financial Services Inc. signing as attorney-in-fact for Patrick W. Smith, indicating UBS is authorized to act on his behalf for this Rule 144 transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 04:02 PM EDT Accepted by SEC EDGAR 09/08/2026 - 04:01 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001167028
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	AXON ENTERPRISE, INC.
SEC File Number	001-16391
Address of Issuer	17800 N. 85TH ST. SCOTTSDALE ARIZONA 85255
Phone	480-991-0797
Name of Person for Whose Account the Securities are To Be Sold	SMITH PATRICK W
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. Eleven Madison Avenue 4th Floor New York NY 10010	10000	5060300.00	81237415	09/08/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/15/2021	Option Exercise	Issuer			10000	11/15/2021	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Patrick W. Smith 17800 N. 85th ST. Scottsdale AZ 85255	Common	06/29/2026	10000	5000018.00
Patrick W. Smith 17800 N. 85th ST Scottsdale AZ 85255	Common	07/07/2026	10000	6437894.85
Patrick W. Smith 17800 N. 85th ST. Scottsdale AZ 85255	Common	08/07/2026	10000	5488963.00

144: Remarks and Signature

Remarks
Date of Notice	09/08/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/12/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc, as attorney-in-fact for Patrick W. Smith
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)